S&P 500

5.460,48

-0,41%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Orphazyme AS (ORPH)
Orphazyme AS (ORPH) Notícias

ORPH

Orphazyme AS (ORPH)

Orphazyme AS

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ORPH

1

Data	Hora	Fonte	Título	Código	Companhia
10/02/2023	09:07	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:ORPH	Orphazyme AS
09/06/2022	07:03	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ORPH	Orphazyme AS
16/05/2022	17:31	Edgar (US Regulatory)	Amended Notification That Form 20-f Will Be Submitted Late (nt 20-f/a)	NASDAQ:ORPH	Orphazyme AS
31/03/2022	18:42	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(b) (15-12b)	NASDAQ:ORPH	Orphazyme AS
24/03/2022	07:05	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:ORPH	Orphazyme AS
22/03/2022	09:02	Dow Jones News	Orphazyme Begins Delisting ADSs From Nasdaq	NASDAQ:ORPH	Orphazyme AS
21/03/2022	17:24	Edgar (US Regulatory)	Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)	NASDAQ:ORPH	Orphazyme AS
04/11/2021	09:00	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:ORPH	Orphazyme AS
15/10/2021	17:17	Edgar (US Regulatory)	Securities Registration (foreign Private Issuer) (f-3)	NASDAQ:ORPH	Orphazyme AS
24/08/2021	09:00	Business Wire	CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C	NASDAQ:ORPH	Orphazyme AS
09/07/2021	08:25	GlobeNewswire Inc.	AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic The...	NASDAQ:ORPH	Orphazyme AS
28/06/2021	07:57	Dow Jones News	Orphazyme Shrinks Workforce Following FDA Response on Arimoclomol	NASDAQ:ORPH	Orphazyme AS
21/06/2021	13:39	TipRanks	Orphazyme: Unclear Path Ahead Merits a Downgrade	NASDAQ:ORPH	Orphazyme AS
18/06/2021	13:07	Dow Jones News	Orphazyme, CytRx Shares Slide as FDA Rejects Arimoclomol	NASDAQ:ORPH	Orphazyme AS
18/06/2021	08:10	Dow Jones News	Orphazyme Shares Plummet After FDA Turns Away Arimoclomol Application	NASDAQ:ORPH	Orphazyme AS
17/06/2021	11:06	TipRanks	Orphazyme (ORPH) Share Price Rose By Almost 61%; What are the Catalysts?	NASDAQ:ORPH	Orphazyme AS
10/05/2021	09:05	Business Wire	Open Orphan plc Announces £3m COVID-19 Challenge Virus Manufacturing Contract	NASDAQ:ORPH	Orphazyme AS
30/04/2021	17:15	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:ORPH	Orphazyme AS
01/04/2021	17:30	Business Wire	CytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myosi...	NASDAQ:ORPH	Orphazyme AS
17/02/2021	11:25	Business Wire	Ethics Approval Granted for Open Orphan’s COVID-19 Human Challenge Study Model	NASDAQ:ORPH	Orphazyme AS
11/02/2021	18:17	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:ORPH	Orphazyme AS
31/12/2020	16:00	Business Wire	CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C	NASDAQ:ORPH	Orphazyme AS
07/12/2020	12:50	Business Wire	CytRx Announces Orphazyme’s U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease T...	NASDAQ:ORPH	Orphazyme AS
22/06/2005	13:26	Business Wire	Orphan Medical Stockholders Approve Acquisition by Jazz Pharmaceuticals, Inc.	NASDAQ:ORPH	Orphazyme AS
23/02/2005	11:35	PR Newswire (US)	Orphan Medical Sees Lead Product Growing to $20 Million This Year	NASDAQ:ORPH	Orphazyme AS